HugoScore hugoscore.org

Patient community and AI mentor

Belong.Life

BelongAI Dave offers patient cancer questions, information, and document sharing. Its policy also permits commercial content and secondary use of depersonalized history. The posture is Mixed, with consumer and enterprise deployments assessed separately.

Document-based draft Read full report Open directory

Checklist assessment dated October 30, 2026. Independent confirmation is incomplete. Hugo has not personally verified this service.

Mixed7 of 12 agency checks metDocument-based draft. Independent confirmation incomplete; not product-tested.How categories work

Agency checklist · October 30, 2026

Mixed 7 of 12 yes

Document-based draft. Independent confirmation is incomplete. Hugo has not personally verified this service.

Assessed function: Belong.Life BelongAI Dave AI cancer mentor (consumer app and community); enterprise private-label, pharma and clinical tools not assessed

Astra review conflicted: OpenAI model in role record.

A no can mean missing documentation or institution-dependent control; it does not by itself establish harmful behavior. These categories are not clinical safety or product-quality ratings.

  • Public documents do not establish actual product behavior.
  • The independent review screened rules and selected evidence; it did not replicate all twelve answers for this tool.
See all twelve answers and their evidence
QuestionAnswerEvidence / reviewSource and reasoning
1. Told it is AIYesdocumented
Not independently replicated
provide automated AI-generated responses Source

AI Mentor Terms of Service. The service is named 'Dave the AI Cancer Mentor'.

2. Operator and model maker namedNonot-documented
Not independently replicated
Quotation not recorded; evidence repair pending. Source

Belongtail Ltd (Israeli company) is named as data controller. How-it-works page says 'proprietary conversational AI technology' and 'LLM (large language model engines)' with no model maker named.

3. Patient chooses to use itYesdocumented
Not independently replicated
allow Users to ask free text questions in certain health-related fields Source

Patient downloads or registers and asks questions. Mentor can nudge users (see question 4). Muting notifications is allowed.

4. Patient sets the taskNodocumented
Not independently replicated
the Service may be able to initiate and encourage further conversation with the User to increase engagement Source

Judgment call. Patient asks free-text questions, but the Terms document operator-initiated engagement prompts, and the operator sells pharma and advertiser access (Belong enterprise pages).

5. Patient can decline or stopYesdocumented
Not independently replicated
allow Users to ask free text questions in certain health-related fields Source

Self-started rule applied (cites question 3 source). Terms: notifications can be stopped by muting the channel.

6. Patient sees the AI outputYesdocumented
Not independently replicated
provide automated AI-generated responses Source

Patient reads the AI's answers directly.

7. Patient can correct or challengeYesdocumented
Not independently replicated
Users can provide feedback on the relevance and helpfulness of the answers Source

Weak yes. Feedback route only. Terms say Belongtail is 'not under any obligation' to use human review of AI content.

8. Patient can get a copyYesdocumented
Not independently replicated
we can provide you all your Personal Information which you provided to us in a structured, commonly used and machine-readable format Source

Request by contacting Belongtail.

9. Patient can deleteYesdocumented
Not independently replicated
deleting your Account from the Service, in which case we will delete any such Personal Information pursuant to any applicable privacy laws Source

Policy also allows retention for legal needs and depersonalized activity history.

10. Training or sale does not override patient choiceNodocumented
Not independently replicated
in order to train our AI models, improve our Services, and create new Services Source

Terms: Belongtail 'may use the Content of your conversations' for this. How-it-works says the AI was trained on user data. No opt-out documented.

11. Patient can run it or take it elsewhereNonot-documented
Not independently replicated
Quotation not recorded; evidence repair pending. Source

Vendor-hosted only. Terms limit use to a personal, non-commercial license.

12. No advertising or data businessNodocumented
Not independently replicated
In those groups you may see advertisements which relate to your type of disease or type of groups. Source

Privacy: ads shown in groups. Belong enterprise pages sell 'Media for Advertisers' and pharma reach. Privacy also allows sharing aggregated data with third parties for research.

Initial coding: Claude Sonnet helpers, compiled by Claude Opus 5.5 (Anthropic). Selective review and corrections: GPT-6 Astra (OpenAI). Editor: Hugo Campos. Acceptance of corrections is not product verification.

Checklist rules · Independent review and limitations · Later evidence follow-up

Earlier v1.3 assessment and control finding

Historical assessment under different rules. It does not set the current checklist zone.

MixedEarlier review, before the published method. Documents only.

Agency finding, before method v1.3

Mixed

Legacy editorial placement, pre-method: 69

This profile has not yet been reviewed under the published method. Its finding and any number are editorial placements made before the method existed.

Evidence
Documentary review. Public sources only, no hands-on testing by HugoScore.
Review status
AI draft. No person has settled the findings.
The question we ask Who does Belong.Life serve in this deployment?
Control Belong.Life BelongAI Dave AI cancer mentor (consumer app and community); enterprise private-label, pharma and clinical tools not assessed
Agency read Mixed
Vendor
Belonglife Inc / Belongtail Ltd (Belong.Life)
Who it serves
Patient-directed cancer questions with commercial-content conditions
Primary User
Cancer patients, multiple sclerosis patients, caregivers, and condition communities
Control Model
Vendor-hosted public service. Controls and downstream processors depend on the assessed deployment.
Patient Impact
Cancer information, community experience and a shareable binder can broaden patient questions. Per-answer citations, correction of mentor interpretations and moderation appeals were not verified.
Profile Status
Document-based draft
Last assessed
Oct 30, 2026
Earlier review confidence
Moderate for public product and policy claims, limited for actual patient experience (AI-assisted draft)
Earlier review model
OpenAI Codex / GPT-6
Earlier human review record
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.

Earlier evidence and assessment

The sections below preserve the earlier review. Its classifications and provenance are historical; the checklist above gives the current draft classification.

Earlier finding · Legacy editorial placement, pre-method: 69

Method v1.3. The control line is evidence for how the agency finding arose, not a quality score. Legacy editorial placement, pre-method: 69. Not comparable with v1.3 positions.

Mixed

BelongAI Dave offers patient cancer questions, information, and document sharing. Its policy also permits commercial content and secondary use of depersonalized history. The posture is Mixed, with consumer and enterprise deployments assessed separately.

Patient agency

How this tool changes agency

Expands agency when

Cancer information, community experience and a shareable binder can broaden patient questions. Per-answer citations, correction of mentor interpretations and moderation appeals were not verified.

Limits agency when

Sponsor visibility, mentor source provenance, redirection and correction behavior remain unverified

Patient agency assessment

Who sets and changes the goal?

Patient authority

Patients can ask their own questions and choose document sharing in the described consumer workflow. Sponsor-content mechanisms create additional objectives, but actual steering of clinical recommendations was not established.

What can the patient understand, question, or do?

Critical capacity

Cancer information, community experience and a shareable binder can broaden patient questions. Per-answer citations, correction of mentor interpretations and moderation appeals were not verified.

Can the patient evaluate the conditions of use?

Informed control

The seed's general positive label needs the documented commercial and secondary-use conditions. Account deletion is not a promise to remove every depersonalized derivative.

Text findings

Conditions of use

Published controls and their limits

The seed's general positive label needs the documented commercial and secondary-use conditions. Account deletion is not a promise to remove every depersonalized derivative.

What remains unknown?

Not tested or not established

Sponsor visibility, mentor source provenance, redirection and correction behavior remain unverified

Who evaluated this?

AI-assisted public-source draft

Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.

Sources checked

Source-specific findings and retrieval limitations are recorded in the full report.

Earlier review provenance

Criteria

CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.

Reviewer

AI-assisted public-source reassessment prepared in OpenAI Codex.

AI / model

OpenAI Codex / GPT-6

Human review

Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.

Review date

2026-09-08

Limitations

Sponsor visibility, mentor source provenance, redirection and correction behavior remain unverified No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.

Earlier review method

Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.

Document-based draft · Moderate for public product and policy claims, limited for actual patient experience (AI-assisted draft)